In conclusion, this study is the first to investigate the pathophysiological processes of ARVC using the PKP-2 mutation, which was screened in a clinical setting, to determine whether the expression of Cx43 has a function in the development of ARVC. The gene discussed is GJA1; the disease is Arrhythmogenic right ventricular dysplasia.